Imagine making medicine like baking a cake, but instead of wasting heaps of plastic wrap and using a power-hungry oven, you use a smart, efficient system that cleans up after itself. This work replaces harsh chemicals with water or nothing at all and uses digital twins to predict the best way to build a drug. It's about making the factory as clean as the medicine it produces.
Pharmaceutical manufacturing is a major polluter, contributing up to 8% of global CO2 emissions. Companies struggle to transition to green chemistry without risking production quality, regulatory failure, or economic loss.
A modular digital decision-support tool for sustainability and a series of scaled-up, continuous manufacturing platforms for small molecules, proteins, and RNA.
If you are an API manufacturer dealing with high solvent waste and carbon footprints — this project developed solvent-free and aqueous chemical synthesis that reduces hazardous substances and greenhouse gas emissions.
If you are a producer of RNA or proteins dealing with inefficient batch processing — this project developed continuous biomanufacturing platforms with real-time monitoring to improve material efficiency.
If you are a facility manager dealing with high-emission sterilization and cleaning — this project developed low-emission decontamination technologies using supercritical CO2 to lower energy demand.
Based on available project data, the project uses 'Economy' as a core SELECT criterion to ensure that sustainable process designs remain economically feasible while reducing energy and material waste.
Yes, the project specifically aims to scale up intensified and aqueous processes to a level sufficient for clinical testing and ensures they are easily transferable to a Good Manufacturing Practice (GMP) environment.
Based on available project data, the digital decision-support tool is intended to be publicly accessible, though specific licensing for industrial use is not detailed.
Yes, it establishes harmonized Life Cycle Assessment (LCA) methodologies and sustainability indicators to facilitate regulatory adoption and alignment across the supply chain.
The project runs from November 1, 2024, to October 31, 2030, indicating a long-term development and validation cycle.
The consortium is heavily weighted toward industrial application, with 43 industry partners (80% ratio) and 10 SMEs. This high level of private sector involvement, spanning 14 countries, suggests that the outputs are designed for immediate commercial utility rather than purely academic interest.
Contact Universiteit Gent for technical specifications on SSbD platforms.
Contact us to find a partner within the PharmEco consortium for early adoption of green API synthesis.
